查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813816

美国细胞治疗材料市场：市场规模、份额、趋势分析（按产品、最终用途和地区）、细分市场预测（2025-2033）

U.S. Cell Therapy Raw Materials Market Size, Share & Trends Analysis Report By Product (Media, Sera, Antibodies, Reagents & Buffers), By End-use (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

美国细胞治疗原料市场规模预计在 2024 年达到 20.6 亿美元，预计到 2033 年将达到 93.7 亿美元，2025 年至 2033 年的复合年增长率为 18.42%。

成长的驱动力来自于细胞疗法核准数量的增加、对GMP级高品质投入的需求不断增长以及再生医学的进步。此外，生物製造能力的提升、资金筹措的增加以及CDMO在治疗方法开发中日益增强的作用，也进一步推动了市场的发展，因为该行业优先考虑可靠、扩充性且合规的原材料，以支持临床和商业性的细胞疗法项目。

不断扩大的治疗管道推动了组件需求

受个人化疗法兴起及其製造过程日益复杂化的推动，美国细胞和基因治疗材料产业正经历强劲成长。随着细胞疗法从研究阶段走向商业化，对培养基、质体DNA、生长因子和病毒载体等高高等级原料的需求正在飙升。开发商正在寻求具有一致性、扩充性和合规性的产品，以支持临床和商业规模的生产。此外，原材料供应商加强投资、扩建设施和技术升级，进一步推动了市场发展，并增强了支持先进疗法开发的基础设施。

这种需求体现在不断扩大的细胞和基因治疗候选药物研发管线中，这些候选药物正在临床试验中取得进展。如附表所示，Anitocel（Arcellx/吉利德）和OTL 203（Orchard Therapeutics）等疗法正处于II期和III期临床试验阶段，针对多发性骨髓瘤和Hurler症候群等复杂疾病。这些临床试验以及其他处于早期和中期研发阶段的疗法，展现了正在探索的适应症和技术的多样性。

这些治疗方法的开发在很大程度上依赖可重复且合规的生产所需的专用原料。因此，疗法开发商与原料供应商之间的策略伙伴关係关係日益普遍，凸显了原材料在支持创新和推动美国细胞疗法长期成长方面发挥的关键作用。

目录

第一章 分析方法与范围

第二章执行摘要

第三章市场因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析

第四章 产品业务分析

  • 细分仪表板：依产品
  • 美国细胞治疗原料市场：产品差异分析（按产品）
  • 美国细胞治疗原料市场规模及趋势分析（依产品）（2021-2033）
  • 培养基
    • 文化媒体市场（2021-2033）
  • 电浆
    • 等离子市场（2021-2033）
  • 细胞培养补充剂
    • 细胞培养补充剂市场（2021-2033）
  • 抗体
    • 抗体市场（2021-2033）
  • 试剂和缓衝溶液
    • 试剂和缓衝液市场（2021-2033）
  • 其他的
    • 其他市场（2021-2033）

第五章 按最终用途分類的业务分析

  • 细分仪表板：依最终用途
  • 美国细胞治疗材料市场：按最终用途分類的产品差异分析
  • 美国细胞治疗原料市场规模及趋势分析（依最终用途）（2021-2033）
  • 生物製药和製药公司
    • 生物製药和医药市场（2021-2033）
  • 合约风险评估/合约行销
    • CRO/CMO市场（2021-2033）
  • 其他的
    • 其他市场（2021-2033）

第六章 竞争态势

  • 公司分类
  • 战略地图
  • 公司地位分析（2024年）
  • 公司简介
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Actylis.
    • ACROBiosystems
    • STEMCELL Technologies
    • Grifols, SA
    • Charles River Laboratories
    • RoosterBio, Inc.
    • PromoCell GmbH
    • Danaher
    • Sartorius Stedim Biotech
Product Code: GVR-4-68040-698-7

Market Size & Trends:

The U.S. cell therapy raw materials market size was estimated at USD 2.06 billion in 2024 and is projected to reach USD 9.37 billion by 2033, growing at a CAGR of 18.42% from 2025 to 2033. Growth is driven by the rising number of cell therapy approvals, increasing demand for GMP-grade and high-quality inputs, and advancements in regenerative medicine. In addition, expanding biomanufacturing capabilities, increased funding, and the growing role of CDMOs in therapeutic development are further propelling the market forward, as the industry prioritizes reliable, scalable, and regulatory-compliant raw materials to support clinical and commercial cell therapy programs.

Expanding Therapy Pipelines Drive Demand for Components

The U.S. cell and gene therapy raw materials industry is experiencing strong growth, driven by the increasing number of personalized therapies and the complexity of their manufacturing processes. As cell therapies transition from research to commercialization, demand for high-grade raw materials-such as culture media, plasmid DNA, growth factors, and viral vectors-has surged. Developers seek products that offer consistency, scalability, and regulatory compliance to support both clinical and commercial-scale production. Moreover, rising investments, facility expansions, and technology upgrades by raw material suppliers have further accelerated market momentum, strengthening the infrastructure supporting advanced therapy development.

This demand is reflected in the expanding pipeline of cell and gene therapy candidates progressing through clinical trials. As seen in the accompanying table, therapies like Anito cel (Arcellx/Gilead) and OTL 203 (Orchard Therapeutics) are advancing through Phase II and III stages, targeting complex conditions such as multiple myeloma and Hurler syndrome. These trials, along with others in early and mid-development phases, illustrate the diversity of indications and technologies being pursued.

The development of such therapies relies heavily on specialized raw materials for reproducible and compliant manufacturing. As a result, strategic partnerships between therapy developers and raw material providers are becoming increasingly common, highlighting the foundational role of raw materials in supporting innovation and driving long-term growth across the U.S. cell therapy landscape.

U.S. Cell Therapy Raw Materials Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. cell therapy raw materials market report based on the product, and end use:

  • Product Scope Outlook (Revenue, USD Million, 2021 - 2033)
  • Media
  • Sera
  • Cell Culture Supplements
  • Antibodies
  • Reagents & Buffers
  • Others
  • End Use Scope Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical & Pharmaceutical Companies
  • CROs & CMOs
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. End Use Segment
  • 1.3. Regional Scope
  • 1.4. Estimates and Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising demand for cell therapies
      • 3.2.1.2. Advancements in research and development for cell-based therapies
      • 3.2.1.3. Technological Innovation
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost associated with the production and procurement of raw materials
      • 3.2.2.2. Stringent regulations associated with cell therapies
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. U.S. Cell Therapy Raw Materials Market: Product Movement Analysis
  • 4.3. U.S. Cell Therapy Raw Materials Market Size & Trend Analysis, By Product, 2021 to 2033 (USD Million)
  • 4.4. Media
    • 4.4.1. Media Market, 2021 - 2033 (USD Million)
  • 4.5. Sera
    • 4.5.1. Sera Market, 2021 - 2033 (USD Million)
  • 4.6. Cell Culture Supplements
    • 4.6.1. Cell Culture Supplements Market, 2021 - 2033 (USD Million)
  • 4.7. Antibodies
    • 4.7.1. Antibodies Market, 2021 - 2033 (USD Million)
  • 4.8. Reagents & Buffers
    • 4.8.1. Reagents & Buffers Market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. End-use Business Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. U.S. Cell Therapy Raw Materials Market: End Use Movement Analysis
  • 5.3. U.S. Cell Therapy Raw Materials Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
  • 5.4. Biopharmaceutical & Pharmaceutical Companies
    • 5.4.1. Biopharmaceutical & Pharmaceutical Companies Market, 2021 - 2033 (USD Million)
  • 5.5. CROs & CMOs
    • 5.5.1. CROs & CMOs Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
  • 6.3. Company Position Analysis, 2024
  • 6.4. Company Profiles
    • 6.4.1. Thermo Fisher Scientific Inc.
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Strategic Initiatives
    • 6.4.2. Merck KGaA
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Strategic Initiatives
    • 6.4.3. Actylis.
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial Performance
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Strategic Initiatives
    • 6.4.4. ACROBiosystems
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial Performance
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Strategic Initiatives
    • 6.4.5. STEMCELL Technologies
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial Performance
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Strategic Initiatives
    • 6.4.6. Grifols, S.A.
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial Performance
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Strategic Initiatives
    • 6.4.7. Charles River Laboratories
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial Performance
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Strategic Initiatives
    • 6.4.8. RoosterBio, Inc.
      • 6.4.8.1. Overview
      • 6.4.8.2. Financial Performance
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Strategic Initiatives
    • 6.4.9. PromoCell GmbH
      • 6.4.9.1. Overview
      • 6.4.9.2. Financial Performance
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Strategic Initiatives
    • 6.4.10. Danaher
      • 6.4.10.1. Overview
      • 6.4.10.2. Financial Performance
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Strategic Initiatives
    • 6.4.11. Sartorius Stedim Biotech
      • 6.4.11.1. Overview
      • 6.4.11.2. Financial Performance
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Strategic Initiatives

List of Tables

  • Table 1. U.S. cell therapy raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 2. U.S. cell therapy raw materials market, by end-use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 U.S. cell therapy raw materials market segmentation
  • Fig. 3 Data analysis models
  • Fig. 4 Market formulation and validation
  • Fig. 5 Data validating & publishing
  • Fig. 6 Market research process
  • Fig. 7 Information procurement
  • Fig. 8 Primary research
  • Fig. 9 Market formulation & validation
  • Fig. 10 Commodity flow analysis
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Market trends & outlook
  • Fig. 16 Porter's five force analysis
  • Fig. 17 SWOT analysis, by factor (Political, Economic, Social, Technological, and Legal)
  • Fig. 18 U.S. cell therapy raw materials market: Product outlook key takeaways
  • Fig. 19 U.S. cell therapy raw materials market: Product movement analysis
  • Fig. 20 Media market, 2021 - 2033 (USD Million)
  • Fig. 21 Sera market, 2021 - 2033 (USD Million)
  • Fig. 22 Cell culture supplements market, 2021 - 2033 (USD Million)
  • Fig. 23 Antibodies market, 2021 - 2033 (USD Million)
  • Fig. 24 Reagents & buffers market, 2021 - 2033 (USD Million)
  • Fig. 25 Others market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. cell therapy raw materials market: End-use outlook key takeaways
  • Fig. 27 U.S. cell therapy raw materials market: End-use movement analysis
  • Fig. 28 Biopharmaceutical & pharmaceutical companies market, 2021 - 2033 (USD Million)
  • Fig. 29 CROs & CMOs supplements market, 2021 - 2033 (USD Million)
  • Fig. 30 Others supplements market, 2021 - 2033 (USD Million)